Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
10/16/2009
Trade Name:
CERVARIX
Generic or Proper Name (*):
Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant*
Indications Studied:
Prevention of genital warts caused by HPV 16 and 18
Therapeutic Category:
Preventive Vaccine
Ages Studied:
10-14 years
Study #:
1
Study Type:
Safety/Immunogenicity
Study Design:
Double-blind/Controlled
No Patients:
2067
No Centers:
57
No Countries:
12
BPCA(B), PREA(P):
P
-
-